Status:

NOT_YET_RECRUITING

Transcranial Direct Current Stimulation and Gamified Rehabilitation for Upper Limb Function in Pediatric Brain Damage

Lead Sponsor:

Universidad Francisco de Vitoria

Collaborating Sponsors:

Universidad Nacional de Educación a Distancia

Hospital Beata María Ana

Conditions:

Paediatric Brain Damage

Cerebral Palsy

Eligibility:

All Genders

7-15 years

Phase:

NA

Brief Summary

The goal of this clinical trial is to acknowledge the effects of transcranial direct current stimulation as an adjuvant with gaming rehabilitation for upper limb function rehabilitation in paediatric ...

Detailed Description

Paediatric brain damage is categorized into two main types: cerebral palsy, characterized by permanent impairments in posture and movement due to non-progressive brain injuries during gestation and ea...

Eligibility Criteria

Inclusion

  • Ischemic or hemorrhagic stroke.
  • Traumatic brain injury.
  • Cerebral palsy.
  • Acquired Brain Injury.
  • Other causes of non-progressive brain damage susceptible to treatment with the established procedures.
  • Evolution of the injury of at least one year.
  • Age between 7 and 15 years, with adequate language development and capacity to comprehend the proposed procedure.
  • Neuroimaging study done.
  • Absence of previous brain injuries prior to the one prompting treatment.
  • Score between II and IV on the MACS scale for manual ability assessment.
  • Signed informed consent by the patient and their legal guardian in case the participant is 12 or older. If the participant is younger than 12 years, only the caregiver signed informed consent will be necessary.
  • Increased tone according to the modified Ashworth scale ranging from 1 to 1+.
  • Minimum score of 1 on each item assessed in the Melbourne Assessment 2 scale.

Exclusion

  • Dermatological problems in the electrode application area (psoriasis, dermatitis on the scalp or face).
  • Presence of implants or metal pieces in the head excluding fillings.
  • Pacemakers, medication pumps, stimulators (vagal, cerebral, transcutaneous), ventriculoperitoneal shunts, or aneurysm clips.
  • Neurological disease different from that described in the inclusion criteria.
  • Significant language difficulties that unable proper understanding of activities or severely limit expression.
  • Moderate or severe mood disorders diagnosed by the regular pediatrician.
  • Uncontrolled medical issues (acute phase pathologies without medical or pharmacological treatment with proven efficacy or life-threatening conditions).

Key Trial Info

Start Date :

June 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2026

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT06214364

Start Date

June 1 2024

End Date

January 1 2026

Last Update

May 9 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beata Maria Ana Hospital

Madrid, Spain, 28007